Introduction
Graft-versus-host disease (GVHD) is the main cause of early mortality and morbidity after allogeneic hematopoietic stem cell transplantation (SCT) [1] [2] [3] . Although HLA matching represents the major genetic determinant of the clinical outcome after allogeneic SCT [4-6], GVHD also occurs in HLA identical transplants, indicating that non-HLA immune-associated genes are also involved in the process. Middeleton et al. [7] were the first to report that non-HLA gene polymorphisms were associated with SCT outcomes, showing a potential role of TNF and IL-10 polymorphisms in predicting acute GVHD. Since then, a large number of non-HLA genes, which mainly impact the individual immune response to infections and inflammatory reactions, have been reported to have polymorphisms associated with the risk and severity of GVHD [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . These studies prompted us to better define the impact of non-HLA gene polymorphisms on the SCT outcomes and to incorporate these markers into routine pre-and posttransplant strategies. This review offers current knowledge on the contributions of non-HLA polymorphisms of the donor and recipient in GVHD after allogeneic SCT.
Classification of non-HLA gene polymorphisms
A gene polymorphism refers to an individual variation in the sequence of DNA found to cause a more than 1 % gene variation, which contrasts with a mutation, which is defined as an allele sequence found to have less than 1 % gene variation. A gene polymorphism occurs in non-coding regions more frequently than in coding regions. The non-HLA gene polymorphisms include single nucleotide polymorphisms (SNPs), tandem repeats (TRs) and copy number polymorphisms (CNPs), which are named in an allelebased manner (Fig. 1) .
SNPs are individual variations of a DNA sequence, and more than 13 million SNPs have been identified through the 1000 genomes project [20] . A CNP is a difference in the copies of one or more sections of the DNA between individuals owing to duplication or deletion events, and affects a region one kbp to several Mbp in size [21] [22] [23] [24] . This is in contrast to the TR, such as minisatellites, microsatellites and short tandem repeats, in which a pattern of two to 1000 nucleotides is repeated and the repetitions are directly adjacent to each other.
Studies on the functional effects of gene polymorphisms will be helpful for demonstrating the pathways underlying GVHD. A gene polymorphism is considered to be functional when it affects the protein function or gene expression.
Some polymorphic genes encode proteins which are expressed on the cell surface and give an immunological response when the transplant donor and recipient are not identical, where the polymorphic genes are considered to encode minor histocompatibility antigens (mHAs). mHAs are short peptides that are presented on host HLA molecules and can stimulate alloreactive T-cell immune responses after SCT [25] , which may lead to the development of GVHD. A polymorphic gene can encode mHAs that result in peptide sequences that can influence the intracellular processing or presentation of mHA peptides, and the stimulation of an alloreactive response if donors and recipients differ in their mHA genotypes.
Identification of non-HLA gene polymorphisms associated with GVHD Two approaches are generally used to study non-HLA gene polymorphisms associated with GVHD, namely, candidate gene studies (CGS) and genome-wide association studies (GWAS). The CGS is the approach of choice to test a hypothesis and to confirm the findings of prior studies. Candidate genes are chosen based on their biological significance and/or previous reports showing their association with autoimmune diseases, infection immunity and organ transplant rejection. A genome-wide association study (GWAS) examines many gene polymorphisms with a hypothesis-free basis, and usually focuses on associations of SNPs and CNPs with diseases and traits. The major advantage of a CGS approach is its cost effectiveness and its focus on a particular gene polymorphism with known functional consequences, whereas a GWAS approach is expensive, and the results are often difficult to translate into functional knowledge. On the other hand, the CGS does not generally take into account the influence of confounding factors and considers only gene interactions, whereas the GWAS has the potential to uncover novel SNPs, such as possible biomarkers and therapeutic targets, with no bias.
For both the CGS and GWAS approaches, it is important that the association found in a discovery cohort is repeated using an independent cohort to validate the association. One interesting approach is validation of CGD results by a GWAS. Chien et al. [26] examined whether CGS-identified SNPs had a significant impact on the risk of acute GVHD in a GWAS using an independent cohort, and demonstrated the associations of the IL-2, IL-6, IL-10, CTLA4, HPSE and MTHFR genes with the development of acute GVHD. Validation of the GWAS results using a CGD approach and a functional investigation may also be promising.
Non-HLA polymorphisms associated with GVHD
The non-HLA gene polymorphisms demonstrated by large cohort studies to be associated with GVHD are summarized in Table 1 . It should be noted that the polymorphic genes in the recipients are more commonly identified than those in the donors. Using a GWAS, Ogawa et al. [17] determined that there were more than half a million SNPs in 1598 recipient and unrelated donor pairs, and identified five novel SNPs (rs6937034, rs1137282, rs9657655, rs5998746 and rs11873016) associating with the risk of acute GVHD, which were all in the recipients. Compelling evidence from mouse models of GVHD and clinical data have indicated the importance of the cytokine storm in the pathophysiology of acute GVHD, and polymorphisms in cytokine and chemokine genes, such as IFNG, IL-1, IL-2, IL-6, IL-10, IL-17 and TNF, predict the development and severity of acute GVHD, as well as increases in the circulating levels of these cytokines. Activation of inflammatory pathways through these mediators occurs before infusion of donor T cells, which may account for the findings that many gene recipient-derived polymorphisms were critical for the risk of GVHD. These findings may be beneficial when considering the treatment strategy prior to treatment or during the pathogenesis of acute GVHD.
Polymorphisms of immunoregulatory genes associated with GVHD C-C chemokine receptor type (CCR) 5 is a chemokine receptor and its ligands include C-C motif ligand (CCL) 3, Non-HLA polymorphisms in GVHD 311 CCL4, CCL5 and CCL3L1. A large cohort study demonstrated that the donor CCL5 genotype significantly influenced the risk of severe acute GVHD and disease-free survival [27] . Harkensee et al.
[28] reevaluated 41 previously documented SNPs in two independent, large cohorts, and showed an association of the TNF and CTLA4 SNPs with acute GVHD and an association of the IL-2 SNP with chronic GVHD.
The PTPN22 gene encodes lymphoid-specific phosphatase (Lyp) and is an important negative regulator of T-cell activation involved in the dephosphorylation and inactivation of TCR-associated kinases. A SNP of the PTPN22 promoter gene, rs2488457 (G/C), is associated with the susceptibility to autoimmune diseases. In unrelated bone marrow transplantation, the recipient C/C genotype is associated with a significantly lower incidence of grade II-IV acute GVHD and a higher incidence of relapse, which predict worse survival outcomes for patients with high-risk disease [15] .
Functional polymorphisms IL-17 is the hallmark cytokine of Th17 cells and plays important roles in the host defense, the pathophysiology of autoimmune diseases and organ allograft rejection.
Although several studies using mouse models showed a significant impact of IL-17 on the development of acute GVHD [29] [30] [31] [32] [33] [34] [35] , the results were not consistent. Espinoza et al. were the first to report an association of the rs2275913 SNP (G/A) in the promoter of the IL-17 gene with the development of acute GVHD [17, 36] . Notably, the rs2275913 SNP is located within a binding motif for nuclear factor activated T cells (NFAT), which is a critical regulator of the IL-17 promoter [37] . The same group demonstrated that the A allele of the IL-17 gene makes patients susceptible to acute GVHD because it correlates with more efficient IL-17 secretion through its higher affinity for NFAT than the G allele [17] . These findings suggest not only the functional relevance of the IL-17 promoter SNPs with the development of acute GVHD, but also the involvement of IL-17 in the development of acute GVHD, leading to a hypothesis that IL-17-producing cells can modify the function of host dendritic cells (DCs) through unknown mechanisms. The direct interaction between IL-17 and host DCs may be supported by the fact that DCs express IL-17 receptors [38] . A better understanding of the molecular mechanism by which this promoter SNP controls the production of IL-17 may therefore offer some novel therapeutic insights into the mechanisms underlying the development of other IL-17-related diseases, including rheumatoid arthritis, periodontal disease, 
Conclusion
The determination of the non-HLA genotypes associated with GVHD prior to transplantation will provide patients an opportunity to receive optimal strategies in terms of the selection of the donor, type of graft, conditioning treatment and GVHD prophylaxis. However, several issues remain unresolved that need to be addressed before mainstream non-HLA genotyping can be implemented in clinical practice. First, the abundance of non-HLA gene polymorphisms identified should be validated by individual, multiracial cohorts irrespective of whether CGS and GWAS approaches were used, because the study populations may critically impact on results, as has also been seen in HLA association studies [4, 45, 46] . Second, whether a polymorphic gene has a functional role and mHA nature should be determined to obtain a better understanding of the molecular mechanisms by which the gene polymorphism can influence the GVHD, offering novel therapeutic insights into GVHD, as well as other autoimmune diseases in which the polymorphic gene is involved. There is also a possibility that the gene polymorphism of interest may coordinate with other genes, and/or have close linkage with another gene with functional and/or immunogenic properties. Finally, systemic discovery of new genetic biomarkers using GWAS will add weight in the decade ahead, but informed consent and privacy protection remain issues that need specific attention, because GWAS create a large amount of individual-specific digital information that is easy to share across international borders [47] .
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